| Literature DB >> 31772396 |
Ardyan Wardhana1, Sudadi Sudadi1.
Abstract
BACKGROUND AND AIMS: A previous meta-analysis reported that scalp block had limited benefits (low-quality evidence) compared to no-scalp block modalities for analgesia after craniotomy. However, it included studies using two different pain intensity measurement scales. Therefore, we performed another meta-analysis using a single scale.Entities:
Keywords: Analgesia; craniotomy; pain; postsurgery; scalp block
Year: 2019 PMID: 31772396 PMCID: PMC6868657 DOI: 10.4103/ija.IJA_315_19
Source DB: PubMed Journal: Indian J Anaesth ISSN: 0019-5049
Figure 1Study flow chart (as per PRISMA guideline)
Included trials
| Author | Year | Timing | Scalp block | Volume (ml) | Control | Pain intensity assessment | Scale | Rescue analgesia | Adverse outcomes | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gazoni | 2008 | Preoperative | 0.5% ropivacaine | 30 | 14 | Placebo | 16 | 1, 2, 4 h | VAS 1-10 | Morphine | No report |
| Choi | 2009 | Postoperative | 0.75% ropivacaine | 16 | Placebo | 16 | 0.5, 1, 2, 4, 6, 12, 24, and 48 h | VAS 1-100 | Tramadol | No report | |
| Jayaram | 2016 | Preoperative | 0.5% bupivacaine/2% lidocaine | 30 | 20 | Bilateral maxillary block bupivacaine 0.5%/lidocaine 2% | 20 | 1, 2, 4, 12 h | VAS 1-10 | Diclofenac | None |
| Nguyen | 2001 | Postoperative | 0.75% ropivacaine | 20 | 20 | Placebo | 20 | 4, 8, 12, 16, 20, 24, and 48 h | VAS 1-10 | Codeine | No report |
| Tuchinda | 2010 | Preoperative | 0.25% bupivacaine with 1:200.000 adrenaline | 20 | Placebo | 20 | 0.5, 1, 1.5, 2, 6, 12, and 24 | VAS 1-10 | Morphine PCA | None | |
| 0.5% bupivacaine with 1:200.000 adrenaline | 20 | ||||||||||
| Akcil | 2017 | Preoperative | 0.5% bupivacaine | 20 | 15 | Scalp infiltration 0.5% bupivacaine | 15 | 10 m, 1, 2, 6, 12, and 24 h | VAS 1-10 | Morphine PCA | No report |
| Placebo | 15 | ||||||||||
| Can and Bilgin[ | 2017 | Preoperative | 0.5% bupivacaine | 20 | 30 | Placebo | 30 | 2, 4, 8, 16, and 24 h | VAS 1-10 | Meperidine | None |
| 0.5% levobupivacaine | 20 | 30 | |||||||||
| Rigamonti | 2013 | Postoperative | 0.5% bupivacaine with 1:200.000 adrenaline | 20 | 44 | Placebo | 45 | 1,2,4,8,12,18,24 | VAS 1-10 | Hydromorphone PCA | No report |
| Dudko | 2014 | Postoperative | 0.25% bupivacaine/1% lidocaine with 1:200.000 adrenaline | 20 | 25 | Systemic paracetamol 1 g/Ketoprofen 2 mg/kg | 25 | 1, 3, 6, and 24 h | VAS 1-100 | Ketorolac and Paracetamol | No report |
| Scalp infiltration 0.25% bupivacaine/1% lidocaine with 1:200.000 adrenaline | 25 | 1, 3, 6, and 24 h | |||||||||
| Ayoub | 2006 | Post-operative | 0.5% bupivacaine/2% lidocaine | 20 | 25 | Systemic morphine 0.1 mg/kg | 25 | 1,2,4,8,12,16, and 24 h | NRS 1-10 | Codeine | No report |
Figure 2Risk of bias assessment summary
Figure 3Funnel plot of comparison Scalp block vs. no-scalp block, outcome at very early 24 h period postoperatively
GRADE assessment results
| Comparison | Outcomes | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication of bias | GRADE |
|---|---|---|---|---|---|---|---|
| Vs. no-scalp block | Very Early | Serious | Severe | No at all | No | Presence | Very low |
| Early | Serious | Some | No at all | Some | Presence | Very Low | |
| Intermediate | Serious | Some | No at all | No | Presence | Low | |
| Late | Serious | No | No at all | No | Presence | Low | |
| Very Late | Serious | Some | No at all | No | Presence | Very Low | |
| Vs. placebo | Very Early | Serious | Severe | No at all | No | Presence | Very low |
| Early | Serious | No | No at all | No | Presence | Low | |
| Intermediate | Serious | No | No at all | Some | Presence | Low | |
| Late | Serious | No | No at all | Some | Presence | Low | |
| Very Late | Serious | Some | No at all | Some | Presence | Very low | |
| Vs. no-scalp block | Opioid consumption | Serious | Some | No at all | Some | Presence | Very low |
| Vs. placebo | Opioid consumption | Serious | Severe | No at all | Some | Presence | Very low |
Figure 4Forest plot of pain intensity outcome
Summary of meta-analysis result
| Vs. no-scalp block | All studies | Preoperative | Postoperative | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Subgroup | Effect size (95% CI) | Effect size (95% CI) | Effect size (95% CI) | ||||||
| Pain intensity after surgery | |||||||||
| Very early period | 7 (371) | −1.37 [−2.23, −0.50] | 70% | 4 (175) | −1.40 [−2.59, −0.21] | 57% | 3 (196) | −1.27 [−2.72, 0.17] | 76% |
| Early period | 9 (501) | −1.16 [−2.09, −0.24] | 57% | 5 (265) | −1.11 [−2.36, 0.15] | 63% | 4 (236) | −1.15 [−2.97, 0.66] | 56% |
| Intermediate | 7 (431) | −0.44 [−1.03, 0.15] | 43% | 3 (195) | −0.12 [−0.62, 0.37] | 17% | 4 (236) | −1.03 [−1.77, −0.29] | 0% |
| Late period | 7 (396) | −0.50 [−1.06, 007] | 25% | 4 (235) | −0.43 [−0.71, −0.15] | 0% | 3 (161) | −1.24 [−2.91, 0.43] | 57% |
| Very late period | 7 (431) | −0.54 [−1.37, 0.29] | 77% | 3 (195) | −0.50 [−1.79, 0.78] | 78% | 4 (236) | −0.62 [−1.94, 0.70] | 77% |
| 24 h total opioid consumption | 7 (346) | −0.36 [−0.76, 0.04] | 68% | 3 (135) | −0.61 [−1.24, 0.01] | 65% | 4 (211) | −0.18 [−0.67, 0.31] | 66% |
| Vs. placebo | All studies | Preoperative | Postoperative | ||||||
| Subgroup | Effect size (95% CI) | Effect size (95% CI) | Effect size (95% CI) | ||||||
| Pain intensity after surgery | |||||||||
| Very early period | 5 (241) | −1.39 [−2.88, 0.11] | 87% | 3 (120) | −1.73 [−3.37, −0.09] | 76% | 2 (121) | −0.56 [−1.50, 0.38] | NA |
| Early period | 7 (371) | −1.33 [−2.53, −0.13] | 74% | 4 (210) | −1.38 [−3.12, 0.35] | 80% | 3 (161) | −1.15 [−2.97, 0.66] | 56% |
| Intermediate | 6 (341) | −0.09 [−0.61, 0.44] | 14% | 3 (180) | 0.06 [−0.39, 0.51] | 0% | 3 (161) | −0.77 [−1.86, 0.33] | 1% |
| Late period | 6 (341) | −0.53 [−1.23, 0.17] | 39% | 3 (180) | −0.33 [−0.78, 0.12] | 0% | 3 (161) | −1.24 [−2.91, 0.43] | 57% |
| Very late period | 6 (341) | −0.22 [−1.01, 0.56] | 67% | 3 (180) | −0.37 [−1.35, 0.60] | 60% | 3 (161) | −0.19 [−1.47, 1.10] | 67% |
| 24 h total opioid consumption | 6 (281) | −0.53 [−1.07, 0.02] | 78% | 3 (120) | −0.80 [−1.74, 0.14] | 81% | 3 (161) | −0.28 [−0.98, 0.42] | 77% |
Figure 5Forest plot of opioid consumption outcome